Page 54 - Demo

Chapter 25220. Simacek J, Dimian AF, McComas JJ. Communication Intervention for Young Children with Severe Neurodevelopmental Disabilities Via Telehealth. Journal of autism and developmental disorders 2017;47(3):744-767. 21. Camfield P, Gordon K, Dooley J, Camfield C. Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: Six “N of 1” trials. Journal of Child Neurology 1996;11(4):341-343.22. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Systematic reviews 2016;5(1):210. 23. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ 2016;350:h1738.24. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer’s disease. Alzheimer’s & dementia 2009;5(5):406-418.25. Marholin D, Pohl RE, Stewart RM, Touchette PE, Townsend NM, Kolodny EH. Effects of diet and behavior therapy on social and motor behavior of retarded phenylketonuric adults: An experimental analysis. Pediatric Research 1978;12(3):179-187. 26. Fisch GS, Cohen IL, Gross AC, Jenkins V, Jenkins EC, Brown WT. Folic acid treatment of fragile X males: A further study. American Journal of medical genetics 1988;30(1-2):393-399.27. Giffin FD, Clarke JTR, D’entremont DM. Effect of Dietary Phenylalanine Restriction on Visual Attention Span in Mentally Retarded Subjects with Phenylketonuria. Canadian Journal of Neurological Sciences 1980;7(2):127-131. 28. Hackett A, Gillard J, Wilcken B. n of 1 trial for an ornithine transcarbamylase deficiency carrier. Molecular genetics and metabolism 2008;94(2):157-161.29. Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonusdystonia syndrome with tetrabenazine. Parkinsonism & related disorders 2014;20(12):1423-1426.30. Khasnavis T, Torres RJ, Sommerfeld B, Puig JG, Chipkin R, Jinnah HA. A double-blind, placebocontrolled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. Molecular genetics and metabolism 2016;118(3):160-166. 31. Tierney E, Conley SK, Goodwin H, Porter FD. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. American journal of medical genetics Part A 2010;152(1):91-95.32. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. Journal of clinical epidemiology. 2011;64(10):1085-1094. 33. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users’ guides to the medical literature: XXV. Evidence-based medicine: Principles for applying the users’ guides to patient care. Journal of the American Medical Association 2000;284(10):1290-1295. 34. Curatolo P, Moavero R. mTOR Inhibitors in Tuberous Sclerosis Complex. Current neuropharmacology 2012;10(4):404-415. 35. Shapiro EG, Escolar ML, Delaney KA, Mitchell JJ. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses. Molecular Genetics and Metabolism 2017;122:8-16. 36. Jansen DEMC, Krol B, Groothoff JW, Post D. People with intellectual disability and their health problems: A review of comparative studies. Journal of Intellectual Disability Research 2004;48(2):93-102. 37. Nikles J, Mitchell GK, Schluter P, et al. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: The case of palliative care. Journal of clinical epidemiology 2011;64(5):471-480. 38. Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down’s syndrome. The Lancet Neurology 2016;15(6):622-636. 39. Van Eeghen AM, Black ME, Pulsifer MB, Kwiatkowski DJ, Thiele EA. Genotype and cognitive phenotype of patients with tuberous sclerosis complex. European Journal of Human Genetics 2012;20(5):510-515. Annelieke Muller sHL.indd 52 14-11-2023 09:07